Table 6.
Meta‐analyses of neoadjuvant therapy for BR pancreatic cancer
| Author | Year | Number of study (Study design) | Period | n | NAT | UpS | ||
|---|---|---|---|---|---|---|---|---|
| RR, % | R0 rate, % | MST, mo | MST, mo | |||||
| Tang 146 | 2016 | 18 (2 Pros/16 Retr) | 1999‐2014 | 959 | 65.3 | 57.4 | 25.9 | 11.9 |
| Zhang 147 | 2017 | 39 (39 Pros) | 2005‐215 | 1458 | 40.2 | 79.4 | 16.2 | |
| Versteijine 148 | 2018 | 38 (3 RCTs/21 Pros/ 4 Retr) | 2005‐2016 | 9621 | 65.0 | 88.6 | 19.2 | 12.8 |
| Unno 149 | 2019 | 6 a (2 RCT/4 Retr) | 2011‐2018 | ‐ | OS: HR 0.66 (0.50‐0.87), P = .003 | |||
| Janssen 150 | 2019 | 24 (8 Pros/16 Retr) | 2012‐2017 | 313 | 67.8 | 83.9 | 22.2 | |
| Pan 153 | 2020 | 17 a (3 RCT/5 Pros/9 Retr) | 2011‐2018 | 2286 | OR 0.69 (0.41‐1.16), P = .159 | OR 4.75 (2.85‐7.92), P < .001 | HR 0.49 (0.37‐0.65), P < .001 | |
| Cloyd 69 | 2020 | 6 a (6 RCT) | 2015‐2020 | 850 | Risk ratio 0.93, (0.82‐1.04) | Risk ratio 1.51, (1.18‐1.93) | HR 0.73 (0.61‐0.86) | |
Abbreviations: BR, borderline resectable pancreatic cancer; HR, hazard ratio.; mo, months; MST, median overall survival; NAT, neoadjuvant therapy; OR, odds ratio; OS, overall survival; Pros, prospective study; RCT, randomized controlled trial; Retr, retrospective study; RR, resection rate; UpS, upfront surgery.
a
Including studies for potentially resectable pancreatic cancer.